Erratum to Chronic L-DOPA induces hyperactivity, normalization of gait and dyskinetic behavior in MitoPark mice [Genes, Brain and Behavior, (2015), 14: 260-270]. doi: 10.1111/gbb.12210;Chronic L-DOPA induces hyperactivity, normalization of gait and dyskinetic behavior in MitoPark mice

Genes, Brain and Behavior

Volumn 14, Issue 3, 2015, Pages 260-270

  Gellhaar, S ^a   Marcellino, D ^a,b   Abrams, M B ^a   Galter, D ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSIDAD DE LA LAGUNA   (Spain)

Author keywords

Automated gait analysis system; Bilateral dyskinesia model; Dyskinesia score; L DOPA induced dyskinesia; Parkinson's disease

Indexed keywords

LEVODOPA; PRODYNORPHIN; BENSERAZIDE;

AGE DISTRIBUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; CYLINDER TEST; DYSKINESIA; FEMALE; GAIT; GENE EXPRESSION; HYPERACTIVITY; LOCOMOTION; LONG TERM CARE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; ANIMAL BEHAVIOR; C57BL MOUSE; DISEASE MODEL; DRUG ADMINISTRATION; DRUG EFFECTS; DYSKINESIA, DRUG-INDUCED; MOTOR ACTIVITY; PARKINSON DISEASE; PATHOPHYSIOLOGY; RANDOMIZATION;

ANIMALIA; MUS; RODENTIA;

ANIMALS; BEHAVIOR, ANIMAL; BENSERAZIDE; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; DYSKINESIA, DRUG-INDUCED; FEMALE; GAIT; LEVODOPA; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; PARKINSON DISEASE; RANDOM ALLOCATION;

EID: 84925448108     PISSN: 16011848     EISSN: 1601183X     Source Type: Journal    
DOI: 10.1111/gbb.12218     Document Type: Erratum

References (27)

1. Amende, I., Kale, A., McCue, S., Glazier, S., Morgan, J.P. & Hampton, T.G. (2005) Gait dynamics in mouse models of Parkinson's disease and Huntington's disease. J Neuroeng Rehabil 2, 20.
2. Andersson, M., Hilbertson, A. & Cenci, M.A. (1999) Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol Dis 6, 461-474.
3. Blin, O., Ferrandez, A.M., Pailhous, J. & Serratrice, G. (1991) Dopa-sensitive and dopa-resistant gait parameters in Parkinson's disease. J Neurol Sci 103, 51-54.
4. Blumstein, D.T., Daniel, J.C., Evans, C.S. (2006) JWatcher 1.0: An Introductory User's Guide (Computer software). University of California, Los Angeles, CA.
5. Cenci, M.A., Lee, C.S. & Bjorklund, A. (1998) L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 10, 2694-2706.
6. Chuang, C.S., Su, H.L., Cheng, F.C., Hsu, S.H., Chuang, C.F. & Liu, C.S. (2010) Quantitative evaluation of motor function before and after engraftment of dopaminergic neurons in a rat model of Parkinson's disease. J Biomed Sci 17, 9.
7. Ding, Y., Restrepo, J., Won, L., Hwang, D.Y., Kim, K.S. & Kang, U.J. (2007) Chronic 3, 4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease. Neurobiol Dis 27, 11-23.
8. Ding, Y., Won, L., Britt, J.P., Lim, S.A., McGehee, D.S. & Kang, U.J. (2011) Enhanced striatal cholinergic neuronal activity mediates L-DOPA-induced dyskinesia in parkinsonian mice. Proc Natl Acad Sci U S A 108, 840-845.
9. Ekstrand, M.I. & Galter, D. (2009) The MitoPark mouse - an animal model of Parkinson's disease with impaired respiratory chain function in dopamine neurons. Parkinsonism Relat Disord 15(Suppl 3), S185-S188.
10. Ekstrand, M.I., Terzioglu, M., Galter, D., Zhu, S.W., Hofstetter, C., Lindqvist, E., Thams, S., Bergstrand, A., Hansson, F.S., Trifunovic, A., Hoffer, B., Cullheim, S., Mohammed, A.H., Olson, L. & Larsson, N.G. (2007) Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc Natl Acad Sci U S A 104, 1325-1330.
11. Fox, S.H. & Brotchie, J.M. (2010) The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future. Prog Brain Res 184, 133-157.
12. Galter, D., Pernold, K., Yoshitake, T., Lindqvist, E., Hoffer, B., Kehr, J., Larsson, N.G. & Olson, L. (2010) MitoPark mice mirror the slow progression of key symptoms and L-DOPA response in Parkinson's disease. Genes Brain Behav 9, 173-181.
13. Gonzalez-Aparicio, R. & Moratalla, R. (2014) Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson s disease. Neurobiol Dis 62, 416-425.
14. Guillot, T.S., Asress, S.A., Richardson, J.R., Glass, J.D. & Miller, G.W. (2008) Treadmill gait analysis does not detect motor deficits in animal models of Parkinson's disease or amyotrophic lateral sclerosis. J Mot Behav 40, 568-577.
15. Hampton, T.G. & Amende, I. (2010) Treadmill gait analysis characterizes gait alterations in Parkinson's disease and amyotrophic lateral sclerosis mouse models. J Mot Behav 42, 1-4.
16. Hwang, D.Y., Fleming, S.M., Ardayfio, P., Moran-Gates, T., Kim, H., Tarazi, F.I., Chesselet, M.F. & Kim, K.S. (2005) 3, 4-dihydroxyphenylalanine reverses the motor deficits in Pitx3-deficient aphakia mice: behavioral characterization of a novel genetic model of Parkinson's disease. J Neurosci 25, 2132-2137.
17. Lopez, S., Bonito-Oliva, A., Pallottino, S., Acher, F. & Fisone, G. (2011) Activation of metabotropic glutamate 4 receptors decreases L-DOPA-induced dyskinesia in a mouse model of Parkinson's disease. J Parkinsons Dis 1, 339-346.
18. Lundblad, M., Picconi, B., Lindgren, H. & Cenci, M.A. (2004) A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 16, 110-123.
19. Morin, N., Jourdain, V.A. & Di Paolo, T. (2013) Modeling dyskinesia in animal models of Parkinson disease. Exp Neurol. 256, 105-116.
20. Olanow, C.W., Nakano, K., Nausieda, P., Tetrud, J.A., Manyam, B., Last, B., Block, G., Liss, C. & Bush, D. (1991) An open multicenter trial of Sinemet CR in levodopa-naive Parkinson's disease patients. Clin Neuropharmacol 14, 235-240.
21. Pavon, N., Martin, A.B., Mendialdua, A. & Moratalla, R. (2006) ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol Psychiatry 59, 64-74.
22. Schneider, C.A., Rasband, W.S. & Eliceiri, K.W. (2012) NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9, 671-675.
23. Suarez, L.M., Solis, O., Carames, J.M., Taravini, I.R., Solis, J.M., Murer, M.G. & Moratalla, R. (2014) L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice. Biol Psychiatry 75, 711-722.
24. Terzioglu, M. & Galter, D. (2008) Parkinson's disease: genetic versus toxin-induced rodent models. FEBS J 275, 1384-1391.
25. Walker, M.D., Dinelle, K., Kornelsen, R., Lee, A., Farrer, M.J., Stoessl, A.J. & Sossi, V. (2013) Measuring dopaminergic function in the 6-OHDA-lesioned rat: a comparison of PET and microdialysis. EJNMMI Res 3, 69.
26. Westerlund, M., Ran, C., Borgkvist, A., Sterky, F.H., Lindqvist, E., Lundstromer, K., Pernold, K., Brene, S., Kallunki, P., Fisone, G., Olson, L. & Galter, D. (2008) Lrrk2 and alpha-synuclein are co-regulated in rodent striatum. Mol Cell Neurosci 39, 586-591.
27. Westin, J.E., Janssen, M.L., Sager, T.N. & Temel, Y. (2012) Automated gait analysis in bilateral parkinsonian rats and the role of L-DOPA therapy. Behav Brain Res 226, 519-528.